Our research program has led to four patented products, such as tumor suppressor microRNAs (miR-122, miR-125b) and FDA-approved kinase inhibitors (dasatinib, abemaciclib), to treat traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), and other disorders
